Erin McCreary (@erinmccreary) and Ryan Shields (@ryankshields) review expanded MERINO trial data including mortality by pathogen MIC, PK-PD principles, BLING III, beta-lactam therapeutic drug monitoring, linezolid dosing in renal impairment, microbiology issues, and updates from EUCAST.
CORRECTION: Piperacillin-tazobactam was dosed 4.5g IV every 6 hours in the Merino trial.
Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/
07/10/19 • 30 min
Episode Comments
0.0
out of 5
No ratings yet
eg., What part of this podcast did you like? Ask a question to the host or other listeners...
Post
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/breakpoints-474/6-tazobactam-and-tulips-hot-topics-from-eccmid-2019-55128"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to #6 – tazobactam and tulips: hot topics from eccmid 2019 on goodpods" style="width: 225px" /> </a>
Copy